Assessment of Knowledge-Based Planning for Prostate Intensity Modulated Proton Therapy.
IMPT
knowledge-based planning
prostate cancer
Journal
International journal of particle therapy
ISSN: 2331-5180
Titre abrégé: Int J Part Ther
Pays: United States
ID NLM: 101674108
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
11
2020
accepted:
07
04
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
2
11
2021
Statut:
epublish
Résumé
To assess the performance of a proton-specific knowledge based planning (KBPP) model in creation of robustly optimized intensity-modulated proton therapy (IMPT) plans for treatment of patients with prostate cancer. Forty-five patients with localized prostate cancer, who had previously been treated with volumetric modulated arc therapy, were selected and replanned with robustly optimized IMPT. A KBPP model was generated from the results of 30 of the patients, and the remaining 15 patient results were used for validation. The KBPP model quality and accuracy were evaluated with the model-provided organ-at-risk regression plots and metrics. The KBPP quality was also assessed through comparison of expert and KBPP-generated IMPT plans for target coverage and organ-at-risk sparing. The resulting The results demonstrated that robustly optimized IMPT plans created by the KBPP model are of high quality and are comparable to expert plans. Furthermore, the KBPP model can generate more-robust and more-homogenous plans compared with those of expert plans. More studies need to be done for the validation of the proton KBPP model at more-complicated treatment sites.
Identifiants
pubmed: 34722812
doi: 10.14338/IJPT-20-00088.1
pii: Customer: THEIJPT-D-20-00088R1
pmc: PMC8489488
doi:
Types de publication
Journal Article
Langues
eng
Pagination
62-72Informations de copyright
©Copyright 2021 The Author(s).
Déclaration de conflit d'intérêts
Conflicts of Interest: Authors used an in-kind loan Eclipse workstation from Varian Medical Systems for performing proton RapidPlan. The authors have no other relevant conflicts of interest to disclose.
Références
Med Dosim. 2013 Autumn;38(3):344-50
pubmed: 23747223
J Appl Clin Med Phys. 2018 Nov;19(6):209-216
pubmed: 30338911
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):827-34
pubmed: 27020109
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Natl Cancer Inst. 2008 Mar 5;100(5):300-7
pubmed: 18314476
Radiother Oncol. 2014 Dec;113(3):385-91
pubmed: 25465726
Radiat Oncol. 2017 Jan 11;12(1):10
pubmed: 28077128
Cureus. 2018 Dec 6;10(12):e3696
pubmed: 30788187
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):164-172
pubmed: 27979445
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):469-77
pubmed: 26867876
Cancers (Basel). 2015 Mar 30;7(2):574-84
pubmed: 25831258
Radiat Oncol. 2017 May 8;12(1):81
pubmed: 28482845
Phys Med. 2017 Dec;44:199-204
pubmed: 28705507
Med Phys. 2012 Dec;39(12):7446-61
pubmed: 23231294
Radiother Oncol. 2017 Aug;124(2):263-270
pubmed: 28411963
Med Phys. 2011 Feb;38(2):719-26
pubmed: 21452709
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):545-51
pubmed: 21277097
Phys Med. 2017 Apr;36:38-45
pubmed: 28410684
Strahlenther Onkol. 2021 Apr;197(4):332-342
pubmed: 32676685
Med Phys. 2011 May;38(5):2515-22
pubmed: 21776786
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):176-81
pubmed: 23623460
J Appl Clin Med Phys. 2014 May 08;15(3):4611
pubmed: 24892333
Radiat Oncol. 2015 May 10;10:111
pubmed: 25957871
Pract Radiat Oncol. 2012 Oct-Dec;2(4):296-305
pubmed: 24674168
Radiother Oncol. 2011 Jan;98(1):74-80
pubmed: 21176983
Cancers (Basel). 2018 Nov 02;10(11):
pubmed: 30400263
Radiat Oncol. 2018 Sep 10;13(1):170
pubmed: 30201017
Med Phys. 2018 Apr;45(4):1338-1350
pubmed: 29394454
Radiother Oncol. 2016 Sep;120(3):473-479
pubmed: 27427380